News for Helius Medical Technologies Stock (HSDT)

Helius Medical Technologies, Inc. (HSDT) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Zacks Investment Research • 08/06/20

Helius Medical Technologies, Inc. Submits Request for FDA Clearance for PoNS™ Device; Reports Preliminary Financial Results for the Second Quarter and Six Months Ended June 30, 2020

GlobeNewsWire • 08/06/20

Helius Medical Technologies Announces the Dismissal of the Shareholder Class Action Lawsuit

GlobeNewsWire • 07/14/20

Helius Medical Technologies, Inc. Announces FDA Has Granted the PoNS Device Breakthrough Device Designation for the Treatment of Gait Deficits Due to Symptoms of Multiple Sclerosis

GlobeNewsWire • 05/12/20

Helius Medical Technologies, Inc. (HSDT) CEO Phil Deschamps on Q1 2020 Results - Earnings Call Transcript

Seeking Alpha • 05/11/20

UPDATE -- Helius Medical Technologies, Inc. Announces Publication of its PoNS™ Registrational Clinical Trial (TBI-001) in TBI

GlobeNewsWire • 04/30/20

Helius Medical Technologies, Inc. Announces Publication of its PoNS™ Registrational Clinical Trial (TBI-001) in TBI

GlobeNewsWire • 04/30/20

Helius Medical Technologies Appoints Jeffrey S. Mathiesen to its Board of Directors

GlobeNewsWire • 04/22/20

Helius Medical Technologies Announces Authorization from Health Canada to Market the PoNS™ Device for the Treatment of Gait Deficit Due to Mild and Moderate Multiple Sclerosis (MS)

GlobeNewsWire • 03/24/20

Helius Medical Technologies Announces $2.2 Million Registered Direct Offering

GlobeNewsWire • 03/18/20

Helius Medical Technologies, Inc. (HSDT) CEO Phil Deschamps on Q4 2019 Results - Earnings Call Transcript

Seeking Alpha • 03/13/20

Helius Medical Technologies, Inc. Provides Details on Five Recently Authorized PoNS Treatment™ Clinics

GlobeNewsWire • 03/09/20

Helius Medical Technologies Reports Preliminary Unaudited Fourth Quarter and Full Year Unaudited 2019 Financial Results, Provides Commercial and Regulatory Update and Announces Submission to Health Canada for Multiple Sclerosis (MS) Label Expansion and Ne

GlobeNewsWire • 03/02/20

Helius Medical Technologies CEO Philippe Deschamps to Deliver Congressional Briefing on the Latest Technologies, Innovations and Policies in Clinical Neuroscience

GlobeNewsWire • 02/24/20

Helius Medical Technologies Inc. Welcomes Cline Medical Centre as an Authorized PoNS Treatment™ Clinic in Nanaimo, BC

GlobeNewsWire • 02/07/20

Eli Lilly's Acquisition Strategy, And Other News: The Good, Bad And Ugly Of Biopharma

Seeking Alpha • 01/22/20

Helius Medical Technologies, Inc. Issues a Clarification to the News Release Regarding the Agreement with the University Health Network (UHN) Issued at 7:05 am January 16, 2020

GlobeNewsWire • 01/16/20

Helius Medical Technologies, Inc. and University Health Network (UHN) Have Signed an Agreement for UHN and three Neuro-Rehabilitation Centers to Perform a Clinical Experience Program of the PoNS™ Device in Canada

GlobeNewsWire • 01/16/20

Helius Medical Technologies Awarded Pioneer Technology Development Award

GlobeNewsWire • 01/10/20

Independent Research Published Show Positive Results on Translingual Neurostimulation Plus Physical Therapy With Statistically Significant Improvement in Balance and Gait Scores and the Outcomes Were Sustained for 12 Weeks After Discontinuing Treatment

GlobeNewsWire • 12/19/19

Helius Medical Technologies, Inc. Announces Pricing of Public Offering

GlobeNewsWire • 11/22/19

Helius Medical Technologies, Inc. Announces Proposed Public Offering

GlobeNewsWire • 11/21/19

Helius Medical Technologies, Inc. Announces Addition of P3 Health As New Authorized PoNS Treatment™ Clinic in Toronto, Canada

GlobeNewsWire • 11/19/19

Helius Medical Technologies, Inc. (HSDT) CEO Phil Deschamps on Q3 2019 Results - Earnings Call Transcript

Seeking Alpha • 11/12/19

Helius Medical Technologies, Inc. (HSDT) Reports Q3 Loss, Misses Revenue Estimates

Zacks Investment Research • 11/12/19

1
2
3
4
5
6
7

8
9